Risperidone — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Schizophrenia

• Aripiprazole
• Clozapine
• Haloperidol
• Olanzapine
• Quetiapine

Other medications in Mental Health

• Sertraline
• Suvorexant
• Temazepam
• Thioridazine
• Thiothixene
• Tranylcypromine
• Trazodone
• Triazolam

About Risperidone

Risperidone is a vital medication for managing several serious mental health conditions. Understanding how it works and how to access it affordably is crucial.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Risperidone is approved for (FDA label)

Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) 1.1 Schizophrenia Risperidone oral solution is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1) ]. 1.2 Bipolar Mania Monotherapy Risperidone oral solution is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder.

Source: Read the full FDA label on DailyMed. Label effective date: August 30, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Risperidone (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of patients with dementia-related psychosis. [See Warnings and Precautions (5.1) ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for use in patients with dementia-related psychosis. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 4ab6d256-6590-45be-a5df-f505987f96c3. SPL document ID: 38eb3e14-7f79-42c8-ac58-2c050c6295a8. Label effective date: August 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Risperidone (FDA label)

Risperidone is available as a 1 mg/mL oral solution. Oral solution: 1 mg per mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 4ab6d256-6590-45be-a5df-f505987f96c3. SPL document ID: 38eb3e14-7f79-42c8-ac58-2c050c6295a8. Label effective date: August 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Risperidone (FDA label)

The following are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions (5.1) ] Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.2) ] Neuroleptic malignant syndrome [see Warnings and Precautions (5.3) ] Tardive dyskinesia [see Warnings and Precautions (5.4) ] Metabolic Changes (Hyperglycemia and diabetes mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.5) ] Hyperprolactinemia [see Warnings and Precautions (5.6) ] Orthostatic hypotension [see Warnings and Precautions (5.7) ] Falls [see Warnings and Precautions (5.8) ] Leukopenia, neutropenia, and agranulocytosis [see Warnings and Precautions (5.9) ] Potential for cognitive and motor impairment [see Warnings and Precautions (5.10) ] Seizures [see Warnings and Precautions (5.11) ] Dysphagia [see Warnings and Precautions (5.12) ] Priapism [see Warnings and Precautions (5.13) ] Disruption of body temperature regulation [see Warnings and Precautions (5.14) ] The most common adverse reactions in clinical trials (>5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.

Source: FDA prescribing information (DailyMed). Set ID: 4ab6d256-6590-45be-a5df-f505987f96c3. SPL document ID: 38eb3e14-7f79-42c8-ac58-2c050c6295a8. Label effective date: August 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Risperidone (FDA label)

Risperidone oral solution is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone oral solution formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone. Known hypersensitivity to risperidone, paliperidone, or to any excipients in risperidone oral solution. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 4ab6d256-6590-45be-a5df-f505987f96c3. SPL document ID: 38eb3e14-7f79-42c8-ac58-2c050c6295a8. Label effective date: August 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Risperidone (FDA label)

Cerebrovascular events, including stroke, in elderly patients with dementia- related psychosis: Risperidone is not approved for use in patients with dementia-related psychosis. (5.2) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of risperidone and close monitoring. (5.3) Tardive dyskinesia: Consider discontinuing risperidone if clinically indicated. (5.4) Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. (5.5) Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.5) Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. (5.5) Weight Gain: Significant weight gain has been reported.

Source: FDA prescribing information (DailyMed). Set ID: 4ab6d256-6590-45be-a5df-f505987f96c3. SPL document ID: 38eb3e14-7f79-42c8-ac58-2c050c6295a8. Label effective date: August 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Risperidone (FDA label)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Increase the risperidone dose up to double the patient’s usual dose. Titrate slowly. ( 7.1 ) Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Reduce the initial dose.

Source: FDA prescribing information (DailyMed). Set ID: 4ab6d256-6590-45be-a5df-f505987f96c3. SPL document ID: 38eb3e14-7f79-42c8-ac58-2c050c6295a8. Label effective date: August 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.